NCT06690840 2026-01-05
AZALEA
European Institute of Oncology
Phase 2 Recruiting
Clinical Trials
6 trialsNCT06229067 2024-01-29
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT04745975 2022-04-20
Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer
Fudan University
Phase 2 Unknown
NCT03932526 2019-04-30
Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT03358004 2018-10-05
VICTOR3
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT01528826 2012-02-08
NVBOX
Fudan University
Phase 2 Unknown